| Identification | Back Directory | [Name]
Ranibizumab | [CAS]
347396-82-1 | [Synonyms]
Lucentis
Ranibizumab
Unii-zl1R02vt79
Ranibizumab USP/EP/BP
Ranibizumab (anti-VEGF)
Research Grade Ranibizumab(DHD12601)
Ranibizumab - 25mg/ml solution in PBS
RanibizumabQ: What is
Ranibizumab Q: What is the CAS Number of
Ranibizumab Q: What is the storage condition of
Ranibizumab | [Molecular Formula]
C11H12N2O2 | [MOL File]
347396-82-1.mol | [Molecular Weight]
204.225 |
| Chemical Properties | Back Directory | [form ]
Liquid | [color ]
Colorless to light yellow | [Uses]
Ranibizumab, a humanized antigen binding portion of a murine anti- VEGF monoclonal antibody with a mature high affinity for all VEGF isoforms, has been approved as an intravitreal treatment for neovascular AMD and is the first such treatment to improve visual acuity (VA) in neovascular AMD.
CRUISE is multicenter, randomized, double-masked, sham injectioncontrolled Phase III study of 392 participants designed to assess the efficiency and safety profile of ranimizumab for macular edema associated to CRVO. The month 6 result showed that 46.2% (61/132) of patients received 0.3 mg of ranimizumab and 47.7% (62/130) received 0.5 mg of ranimizumab had their vision improved by 15 letters or more compared to 16.9% (22/130) of patients receiving sham injections and mean gain was observed beginning at day seven with an 8.8 and 9.3 letter gain in the 0.3 mg and 0.5 mg study arms of ranimizumab, respectively, compared with 1.1 letters in the sham injection arm. | [CAS DataBase Reference]
347396-82-1 |
| Hazard Information | Back Directory | [Description]
Ranibizumab is a recombinant, humanized, IgG1 monoclonal antibody fragment
(Fab) that neutralizes all active forms of vascular endothelial growth factor
A (VEGF-A), and it is indicated for the treatment of neovascular age-related
macular degeneration (AMD). It consists of a nonbinding human sequence
and a high-affinity binding epitope (Fab fragment) derived from the mouse. The
full-length RhuMab VEGF (bevacizumab) was launched previously by Genentech
for the treatment of colorectal cancer. Both the antibody fragment and the
full-length antibody bind to and inhibit all active forms of VEGF-A and are
derived from the same mouse monoclonal antibody. However, ranibizumab has
been genetically engineered through a process of selective mutation to increase
its affinity for binding and inhibiting the growth factor. | [Originator]
Genentech (US) | [Brand name]
Lucentis |
|
|